Prostate cancer in the ageing male

Journal of Men's Health and Gender

Volumn 1, Issue 1, 2004, Pages 47-54

  Remzi, Mesut ^a   Waldert, Mattias ^a   Djavan, Bob ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGING; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; ETHNOLOGY; HIGH RISK POPULATION; HUMAN; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 16344395366     PISSN: 15718913     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmhg.2004.03.021     Document Type: Article

References (58)

1. Yatani R., Chigusa I., Akazaki K., Stemmermann G.N., Welsh R.A., Correa P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer. 29:1982;611-616
2. Scardino F.T. Early detection of prostate cancer. Urol. Clin. North Am. 16:(4):1989;635-655
3. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics. CA Cancer J. Clin. 53:2003;5-26
4. American Cancer Society. Cancer facts and figures 2003. Atlanta, GA: American Cancer Society; 2003.
5. Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence, and mortality. BJU Int. 90:2002;162-173
6. Gronberg H. Prostate cancer epidemiology. Lancet. 361:2003;859-864
7. Lunenfeld B. The ageing male: demographics and challenges. World J. Urol. 20:2002;11-16
8. Trends in aging - United States and worldwide. MMWR Morb Mortal Wkly Rep 2003;52:101-4, 106.
9. Haas G.P., Sakr W.A. Epidemiology of prostate cancer. CA Cancer J. Clin. 47:1997;273-287
10. The Department of Defense Center for Prostate Disease. Oncology (Huntington) 1999;13:1336, 1339-40.
11. Newcomer L.M., Stanford J.L., Blumenstein B.A., Brawer M.K. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J. Urol. 158:1997;1127-1130
12. Carter HB, Piantadosi, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-6.
13. Scher HI, Isaacs JT, Zelefsky MJ, et al. Prostate cancer. In: Abeloff MD, Armitage JO, Lichter AS, et al., editors. Clinical oncology. 2nd ed. New York: Churchill Livingstone; 2000. p. 1823-84.
14. Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 50:2000;7-33
15. Sarma A.V., Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin. Urol. Oncol. 20:2002;3-9
16. Paquette E.L., Sun L., Paquette L.R., Connelly R., McLeod D.G., Moul J.W. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology. 60:2002;756-759
17. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Lance R., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 132:2002;213-219
18. Smith C.V., Bauer J.J., Connelly R.R., Seay T., Kanc C., Foley J., et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J. Urol. 164:2000;1964-1967
19. National Cancer Institute. Prostate cancer: histologic grade and stage. Available at: http://www.seer.cancer.gov/publications/prostate/grade.html. Accessed April 23, 2003.
20. Helgesen F., Holmberg L., Johansson J.E., Bergstrom R., Adami H.O., et al. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J. Natl. Cancer Inst. 88:1996;1216-1221
21. Djavan B., Moul J.W., Zlotta A., Remzi M., Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur. Urol. 43:(1):2003;12-27
22. Ries LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review 1973-1995. Bethesda, MD: National Cancer Institute; 1998.
23. Chu K.C., Tarone R.E., Freeman H.P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 97:2003;1507-1516
24. Ruchlin H.S., Pellissier J.M. An economic overview of prostate carcinoma. Cancer. 92:2001;2796-2810
25. Chodak G.W., Thisted R.A., Gerber G.S., Johansson J.E., Adolfsson J., Jones G.W., et al. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 33:1994;242-248
26. Albertsen P.C., Hanley J.A., Gleason D.F., Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. J. Am. Med. Assoc. 280:1998;975-980
27. Johansson J.E., Adami H.O., Andersson S.O., Bergstrom R., Adami H.O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. J. Am. Med. Assoc. 277:1997;467-471
28. Aus G., Abbou C.C., Pacik D., Schmid H.P., van Poppel H., Wolf J.M., et al. EAU guidelines on prostate cancer. V.ur Ural. 40:2001;97-101
29. Scherr D., Swindle P.W., Scardino P.T. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 61:(2 Suppl. 1):2003;14-24
30. Menon M., Parulkar B.G., Baker S. Should we treat localized prostate cancer? An opinion. Urology. 46:1995;607-616
31. Fowler F.J. Jr., McNaughton Collins M., Albensen P.C., Zietman A., Elliott D.B., Barry M.J. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. J. Am. Med. Assoc. 283:2000;3217-3222
32. Krahn M.D., Bremner K.E., Asaria J., Alibhai S.M., Narm R., Tomlinson G., et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 60:2002;258-263
33. Samet J., Hunt W.C., Key C., Humble C.G., Goodwin J.S. Choice of cancer therapy varies with age of patient. J. Am. Med. Assoc. 255:1986;3385-3390
34. Lu-Yao G.L., McLerran D., Wasson J., Wennberg J.E. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. J. Am. Med. Assoc. 269:1993;2633-2636
35. Sverson R.K., Montie J.E., Porter A.T., Demers R.Y. Recent trends in incidence and treatment of prostate cancer among elderly men. J. Natl. Cancer Inst. 87:1995;532-534
36. Desch C.E., Penberthy L., Newschaffer C.J., Hillner B.E., Whittemore M., McClish D., et al. Factors that determine the treatment for local and regional prostate cancer. Med. Care. 34:1996;152-162
37. Goodwin J.S., Hunt W.C., Samet J.M. Determinants of cancer therapy in elderly patients. Cancer. 72:1993;560-594
38. Harlan L.C., Potosky A., Gilliland F.D., Hoffman R., Albertsen P.C., Hamilton A.S., et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcome Study. J. Natl. Cancer Inst. 93:(24):2001;1864-1871
39. Bennett C.L., Greenfield S., Aronow H., Ganz P., Vogelzang N.J., Elashoff R.M. Patterns of care related to age of men with prostate cancer. Cancer. 67:1991;2633-2641
40. Post P.N., Kil P.J.M., Hendrikx A.J.M., Janssen-Heijnen M.L.G., Crommelin M.A., Coebergh J.W.W. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 84:1999;652-656
41. Yan Y., Carvalhal C.F., Catalona W.J., Young J.D. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 88:2000;1122-1130
42. Horan A.H., McGehee M. Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy. BJU Int. 85:2000;1063-1066
43. Minino A.M., Smith B.L. Deaths: preliminary data for 2000. Natl. Vital Stat. Rep. 49:2001;1-40
44. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley Jr AG, Wennberg JE, et al. for the Prostate Disease Patient Outcome Research Team. A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993;2:487-93.
45. Johansson J.E. Expectant management of early stage prostatic cancer: Swedish experience. J. Urol. 152:1994;1753-1756
46. Epstein J.I., Walsh P.C., Carmichael M., Brendle C.B., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J. Am. Med. Assoc. 271:1994;368-374
47. Humphrey P.A., Keetch D.W., Smith D.S., Shepherd D.L., Catalona W.J., et al. Prospective characterization of pathological features of proslatic carcinomas detected via serum prostate specific antigen based screening. J. Urol. 155:1996;816-820
48. Barry M.J., Fleming C., Coley C.M., Wasson J.H., Fahs M.C., Oesterling J.E., et al. Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV. Estimating the risks and benefits of an early detection program. Urology. 46:1995;445-461
49. Ross K.S., Carter H.B., Pearson J.D., Guess H.A., et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. J. Am. Med. Assoc. 284:2000;1399-1405
50. Carter H.B., Landis P.K., Metter E.J., Fleisher L.A., Pearson J.D. Prostate-specific antigen testing of older men. J. Natl. Cancer Inst. 91:(20):1999;1733-1737
51. Alibhai S.M.H., Krahn M.D., Cohen M.M., Fleshner N.E., Tomlinson G.A., Naglie G. Is there age bias in the treatment of localized prostate carcinoma? Cancer. 100:(1):2004;72-81
52. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Chron. Dis. 10:1987;373-383
53. Schwartz K.L., Alibhai S.M.H., Tomlinson G., Naglie G., Krahn M.D. Continued undertreatment of older men with localized prostate cancer. Urology. 62:(5):2003;860-865
54. Dahm P., Silverstein A.D., Weizer A.Z., Crisci A., Vieweg J., Paulson D.F. When to diagnose and how to treat prostate cancer in the "not too fit" elderly. Crit. Rev. Oncol./Hematol. 48:2003;123-131
55. Talcott J.A., Rieker P., Clark J.A., Propert K.J., Weeks J.C., Beard C.J., et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J. Clin. Oncol. 16:1998;275-283
56. Lu-Yao G.L., Albertsen P., Warren J., Yao S.L. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology. 54:1999;301-307
57. Stanford J.L., Feng Z., Hamilton A.S., Gilliland F.D., Stephenson R.A., Eley J.W., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. J. Am. Med. Assoc. 283:2000;354-360
58. Walsh P.C. Survival of men with clinically localized prostate cancer detected in the eighth decade of life [comment]. J. Urol. 151:1994;1329